TransMedics Group Inc. (TMDX)
NASDAQ: TMDXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 81.07 0.00%
TMDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.81B
- P/E (TTM)
- 21.00
- Forward P/E
- 35.96
- EPS (TTM)
- $3.86
- Dividend yield
- None
- 52-week range
- 60.11 – 156.00
- Day range
- 80.56 – 83.90
- Volume / Avg
- 962.41K / 813.99K
- Beta
- —
- Shares outstanding
- 34.68M
- Next earnings
- Nov 4, 2026
52-week range
TMDX stock today
TransMedics Group (TMDX) closed at $81.07 on Oct 7, up 0.98% (+$0.79), versus the S&P 500's 0.22% decline. Shares are 48.0% below their 52-week high of $156.00, set on Dec 2, 2025 and 34.9% above the 52-week low of $60.11, in the middle of the past year's range. TMDX is down 33.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 29.6%.
At 21.0x trailing earnings, TransMedics Group trades in line with the peer-group median of 22.5x. Its forward P/E of 36.0x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. TransMedics Group's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About TransMedics Group
Company profileTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Dr. Waleed H. Hassanein M.D.
- Headquarters
- Andover, MA
- Employees
- 898
- IPO year
- 2019
- Website
- transmedics.com
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$99.82+23.13%
- Strong buy 3
- Buy 6
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.27
TMDX news
All TMDX newsTransMedics Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AXGNAxogen Inc. | 36.04 | -0.74% | $2.11B | vs TMDX |
| LIVNLivaNova PLC | 75.93 | +1.33% | $4.17B | vs TMDX |
| CNMDCONMED Corporation | 44.23 | -0.56% | $1.32B | vs TMDX |
| ITGRInteger Holdings Corporation | 126.59 | +0.09% | $4.30B | vs TMDX |
| CBLLCeriBell Inc. | 23.48 | -3.53% | $901.12M | vs TMDX |
| INMDInMode Ltd. | 14.01 | +0.14% | $806.19M | vs TMDX |
| CVCapsoVision Inc. | 6.54 | +0.62% | $348.00M | vs TMDX |
| ELMDElectromed Inc. | 28.20 | -0.25% | $233.70M | vs TMDX |
Indexes, lists and sector
TransMedics Group stock FAQ
What is TransMedics Group's stock price today?
TMDX last traded at $81.07 as of Oct 7, 4:00 PM EDT, up 0.98% on the day. Prices are delayed at least 15 minutes.
When is TransMedics Group's next earnings date?
TransMedics Group is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.27.
What is TMDX's P/E ratio?
TMDX trades at a trailing P/E ratio of 21.00 and a forward P/E of 35.96, compared with a median of 22.5 for its closest peers.
Who is TransMedics Group's CEO?
Dr. Waleed H. Hassanein M.D. is the chief executive officer of TransMedics Group Inc., which has about 898 employees.
What is the TMDX 52-week high?
The 52-week high for TMDX is $156.00 and the 52-week low is $60.11. The stock is currently 48.0% below its high.